Literature DB >> 10609484

Surgical management of lagophthalmos in patients with facial palsy.

H M Foda1.   

Abstract

PURPOSE: A prospective before-and-after trial was designed to evaluate the role of upper-lid gold weight implantation and lower lid lateral canthoplasty in the management of patients with paralytic lagophthalmos. PATIENTS AND METHODS: The study included 40 patients (age range 19 to 72, mean age 46.8), and gold weights varying from 0.6 to 1.6 g were implanted in all 40 patients. Lateral canthoplasty was performed in 14 of the patients who suffered from variable degrees of lower lid laxity. Mean follow-up period was 15.7 months (range 9 to 38).
RESULTS: Complete correction of lagophthalmos and/or ectropion with resolution of preoperative symptoms was achieved in 37 of 40 patients (92.5%), and spontaneous extrusion of the gold weight occurred in only one patient (2.5%).
CONCLUSION: Excellent results were achieved in the management of paralytic lagophthalmos with upper-lid gold weight insertion, and simultaneous lateral canthoplasty proved to be very helpful in patients with significant hypotonia of lower lid.

Entities:  

Mesh:

Year:  1999        PMID: 10609484     DOI: 10.1016/s0196-0709(99)90079-0

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  3 in total

1.  [Implantation of lid weights for therapy of lagophthalmos].

Authors:  T Schrom; A Habermann; K Wernecke; H Scherer
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  Quality of Life in Patients with Unresolved Facial Nerve Palsy and Exposure Keratopathy Treated by Upper Eyelid Gold Weight Loading.

Authors:  Izabela Nowak-Gospodarowicz; Radosław Różycki; Marek Rękas
Journal:  Clin Ophthalmol       Date:  2020-08-05

3.  The Role of Gold Weight Implants in the Management of Paralytic Lagophthalmos.

Authors:  Muammer Melih Şahin; Eray Uzunoğlu; Recep Karamert; Süleyman Cebeci; Gökçen Cesur; Mücahit Yalçin; Mehmet Düzlü; Hakan Tutar; Mehmet Birol Uğur; Alper Ceylan
Journal:  Turk J Med Sci       Date:  2021-06-27       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.